logo

Do you have moderate to severe Atopic Dermatitis (eczema) or Chronic Pruritus (severe continuous itching)?

Atopic Dermatitis, commonly known as eczema, is an inflammatory skin condition that causes itchy, red, and scaly skin.

Chronic Pruritus, commonly known as chronic itch, is an itchy, painful, and/or tingling sensation, that can be present in several areas of the body and can often lead to an increased urge to scratch.

Researchers are testing a new treatment called ATTO-1310 in a study to see if it can reduce symptoms in people who are affected with these conditions.

We are currently recruiting participants aged 18 to 65 years with Atopic Dermatitis (Eczema) or aged 18 to 85 with Chronic Pruritus, to participate in an investigational study.

Compensation for time and travel may be available. There will be no cost to you for being considered or for taking part in this study, and you will be provided with all study medication, examinations, and medical care related to the study.

Join the trial to contribute to the development of this treatment and potentially benefit from its effects.

 


Visits
Total
Length
Procedures
Study Length
Total
12 visits over approximately 22 weeks
Length
2 to 4 hours
Procedures
Blood samples taken throughout the study.
Study Length
Up to 45 days of screening period, one treatment day, and up to approximately 22 weeks of follow up period
Summary
This study is being done to evaluate the safety, effectiveness, and tolerability of the study drug. The study drug is given by subcutaneous injection (SC), an injection under the skin, once during the study. Study participation will last approximately 22 weeks and includes up to 12 visits in total. The study will include a screening phase which can last up to 45 days, followed by a treatment visit and follow up period. Financial compensation available and no cost for participation; study medication and related medical care provided.
Rectangle 191

Are you a researcher or representative of a clinical site?

Join our network of clinical sites and be at the forefront of innovation in clinical research.